The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival

被引:45
|
作者
Brouwer, Nelleke P. M. [1 ]
Van der Kruijssen, Dave E. W. [2 ]
Hugen, Niek [1 ]
de Hingh, Ignace H. J. T. [3 ]
Nagtegaal, Iris D. [4 ]
Verhoeven, Rob H. A. [1 ,5 ]
Koopman, Miriam [2 ]
de Wilt, Johannes H. W. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Surg, Nijmegen, Netherlands
[2] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands
[3] Catharina Hosp, Dept Surg, Eindhoven, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands
[5] Netherlands Comprehens Canc Org IKNL, Dept Res, Utrecht, Netherlands
关键词
LIVER METASTASES; PATTERNS; SIDEDNESS;
D O I
10.1245/s10434-019-08100-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose We explored differences in survival between primary tumor locations, hereby focusing on the role of metastatic sites in synchronous metastatic colorectal cancer (mCRC). Methods Data for patients diagnosed with synchronous mCRC between 1989 and 2014 were retrieved from the Netherlands Cancer registry. Relative survival and relative excess risks (RER) were analyzed by primary tumor location (right colon (RCC), left colon (LCC), and rectum). Metastatic sites were reported per primary tumor location. Survival was analyzed for metastatic sites combined and for single metastatic sites. Results In total, 36,297 patients were included in this study. Metastatic sites differed significantly between primary tumor locations, with liver-only metastases in 43%, 54%, and 52% of RCC, LCC, and rectal cancer patients respectively (p < 0.001). Peritoneal metastases were most prevalent in RCC patients (33%), and lung metastases were most prevalent in rectal cancer patients (28%). Regardless of the location of metastases, patients with RCC had a worse survival compared with LCC (RER 0.81, 95% CI 0.78-0.83) and rectal cancer (RER 0.73, 95% CI 0.71-0.76). The survival disadvantage for RCC remained present, even in cases with metastasectomy for liver-only disease (LCC: RER 0.66, 95% CI 0.57-0.76; rectal cancer: RER 0.84, 95% CI 0.66-1.06). Conclusions This study showed significant differences in relative survival between primary tumor locations in synchronous mCRC, which can only be partially explained by distinct metastatic sites. Our findings support the concept that RCC, LCC and rectal cancer should be considered distinct entities in synchronous mCRC.
引用
收藏
页码:1580 / 1588
页数:9
相关论文
共 50 条
  • [21] Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer.
    Miyamoto, Yuji
    Sakamoto, Yasuo
    Ida, Satoshi
    Watanabe, Masayuki
    Baba, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [22] Sex differences in metastatic surgery following diagnosis of synchronous metastatic colorectal cancer
    Ljunggren, Malin
    Weibull, Caroline E.
    Palmer, Gabriella
    Osterlund, Emerik
    Glimelius, Bengt
    Martling, Anna
    Nordenvall, Caroline
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (03) : 363 - 373
  • [23] Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
    Bahl, Ankur
    Talwar, Vineet
    Sirohi, Bhawna
    Mehta, Prashant
    Arya, Devavrat
    Shrivastava, Gunjan
    Dahiya, Akhil
    Pavithran, K.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [24] Bevacizumab effectiveness and primary tumor location in metastatic colorectal cancer patients.
    He, Wen-zhuo
    Yang, Qiong
    Jiang, Chang
    Liao, Fang-xin
    Liu, Shou-sheng
    Xia, Liang-ping
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [25] Primary tumor location and bevacizumab effectiveness in metastatic colorectal cancer patients.
    He, Wen-zhuo
    jiang, Chang
    Liao, Fang-xin
    Yang, Qiong
    Kong, Peng-fei
    Xia, Liang-ping
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Relationship between primary tumor location and oncogenes mutations in metastatic colorectal cancer
    Calero Braulio, Martin
    Munoz Marta, Llanos
    Beatriz, Alonso
    Sangil Raquel, Hernandez
    Jose Norberto, Batista Lopez
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Prognostic impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) at the salvage lines.
    Nagaoka, Tomoyuki
    Wakatsuki, Takeru
    Shinozaki, Eiji
    Nakayama, Izuma
    Suenaga, Mitsukuni
    Fukuda, Naoki
    Osumi, Hiroki
    Matsushima, Tomohiro
    Ichimura, Takashi
    Ogura, Mariko
    Ozaka, Masato
    Takahari, Daisuke
    Chin, Keisho
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [28] The impact of metastatic sites in metastatic colorectal cancer at initial diagnosis (MCCID)
    Leone, B. A.
    Lacava, J. A.
    Zwenger, A. O.
    Iturbe, J.
    Perez, J. E.
    Machiavelli, M. R.
    Romero, A. O.
    Vallejo, C. T.
    Dominguez, M. E.
    Rodriguez, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer
    Wong, Hui-li
    Lee, Belinda
    Field, Kathryn
    Lomax, Anna
    Tacey, Mark
    Shapiro, Jeremy
    McKendrick, Joe
    Zimet, Allan
    Yip, Desmond
    Nott, Louise
    Jennens, Ross
    Richardson, Gary
    Tie, Jeanne
    Kosmider, Suzanne
    Parente, Phillip
    Lim, Lionel
    Cooray, Prasad
    Ben Tran
    Desai, Jayesh
    Wong, Rachel
    Gibbs, Peter
    CLINICAL COLORECTAL CANCER, 2016, 15 (02) : E9 - E15
  • [30] Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer
    Jordan, Frank
    Grundmann, Nina
    Schenkirsch, Gerhard
    Maerkl, Bruno
    Messmann, Helmuth
    Anthuber, Matthias
    Schmid, Christoph
    Trepel, Martin
    ANTICANCER RESEARCH, 2018, 38 (09) : 5539 - 5546